VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone reflects continued progress across the company's therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary antibody engineering, linker, and conjugation technologies.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary technologies and represents one of its more advanced development programs. The bsADC program is part of VERAXA's diversified oncology pipeline, which spans bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
In addition to the VXA-222 milestone, VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
This dual advancement—pipeline progression and IP expansion—positions VERAXA to capitalize on the growing market for next-generation antibody therapies. The company's focus on bispecific ADCs and T-cell engagers addresses significant unmet medical needs in oncology, potentially offering more effective and targeted treatment options for patients with difficult-to-treat cancers.
The successful completion of the OmniAb collaboration and the subsequent internal development of VXA-222 underscores VERAXA's ability to leverage external partnerships while maintaining internal expertise in antibody engineering. This approach allows the company to accelerate its pipeline while managing costs and risks associated with drug development.
Furthermore, the expansion of the patent portfolio provides a strong foundation for the company's long-term growth. By protecting its proprietary technologies, VERAXA can secure its competitive position and potentially generate revenue through licensing agreements or partnerships.
Investors and industry observers will be watching closely as VERAXA advances VXA-222 through preclinical validation and toward clinical trials. The company's ability to execute on its development plans and bring innovative therapies to market will be critical to its success.
For more information on VERAXA and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA.
